Detalles de la búsqueda
1.
A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma.
Invest New Drugs
; 38(4): 1056-1066, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31444589
2.
Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium-glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus.
Br J Clin Pharmacol
; 85(8): 1808-1819, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31026084
3.
Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin.
Eur J Drug Metab Pharmacokinet
; 39(1): 1-9, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23754514
4.
Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors.
Clin Pharmacokinet
; 63(4): 423-438, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38609704
5.
The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4.
Br J Clin Pharmacol
; 75(2): 440-9, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22642721
6.
Effect of food on the pharmacokinetics of darexaban, an oral direct factor Xa inhibitor, in healthy Japanese subjects.
Int J Clin Pharmacol Ther
; 51(3): 200-6, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23211396
7.
Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects.
Biopharm Drug Dispos
; 34(8): 431-41, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23929659
8.
Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus.
Diabetes Ther
; 11(4): 951-964, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32166619
9.
Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor.
Clin Pharmacokinet
; 59(10): 1273-1290, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32304015
10.
The effect of fluvoxamine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects.
Eur J Clin Pharmacol
; 64(7): 691-5, 2008 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-18438654
11.
Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor.
Clin Pharmacokinet
; 60(9): 1251, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34297319
12.
Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin.
Clin Pharmacokinet
; 53(11): 975-88, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25316572
13.
Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study.
Diabetes Res Clin Pract
; 106(1): 50-6, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25149596
14.
The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoprotein.
Clin Pharmacol Drug Dev
; 3(3): 194-201, 2014 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27128609
15.
Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes.
Diabetes Care
; 36(5): 1260-5, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23359360
16.
Clinical Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Darexaban, an Oral Direct Factor Xa Inhibitor, in Healthy Elderly Japanese Subjects.
Clin Pharmacol Drug Dev
; 2(4): 328-35, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27121937
17.
Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study.
Clin Ther
; 35(8): 1150-1161.e3, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23910665
18.
The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor.
Clin Drug Investig
; 33(7): 489-96, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23733389
19.
Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
Clin Ther
; 34(8): 1761-71, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22795925
20.
Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.
Clin Drug Investig
; 31(12): 839-51, 2011 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21877761